Alphabet’s life sciences arm, Verily, is partnering with the digital pathology platform Lumea to improve the objectivity and efficiency of prostate cancer diagnosis, prognosis and therapy selection.
Verily developed AI systems for digital pathology to reduce variability and maximize insights from biopsy tissues samples, according to a March 16 news release stated.
The collaboration aims to accomplish the following:
1. Enable Verily to validate its Gleason algorithms for prostate cancer by using Lumea’s platform and extensive database of pathology cases.
2. Integrate Verily’s algorithms into Lumea’s digital pathology platform. Pathologists will then have access to Verily’s AI to help identify and grade prostate cancer within their digital workflow.